16:42 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A heterocycloalkynylbenzimide-based dual DDR1/DDR2 inhibitor could be used to probe the role of two proteins in inflammatory diseases. Chemical synthesis and in vitro activity assays of heterocycloalkynylbenzimide analogs identified a compound that...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Transmembrane 4 L six family member 1 (TM4SF1); discoidin domain receptor tyrosine kinase 1 (DDR1); signal transducer and activator of transcripti

Cancer INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting TM4SF1 or its activity could help treat breast cancer. In patients, high levels of TM4SF1 in primary tumor samples were associated with poor metastasis-free survival, high...
08:00 , Feb 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Discoidin domain receptor tyrosine kinase 1 (DDR1); Notch pathway; K-Ras (KRAS)

Cancer INDICATION: Lung cancer Patient sample and mouse studies suggest combining inhibitors of DDR1 and the Notch pathway could help treat KRAS-mutant lung cancer. In 554 tumor samples from patients with lung adenocarcinoma, the presence of mutant...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Discoidin domain receptor tyrosine kinase 1 (DDR1)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest inhibiting DDR1 could help treat cancers resistant to RG7787. In an RG7787-resistant human skin cancer cell line, RG7787 combined with a DDR1 inhibitor increased cell death compared with...
08:00 , Dec 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Hodgkin's lymphoma Discoidin domain receptor tyrosine kinase 1 (DDR1) In vitro studies suggest inhibiting DDR1 could help...
07:00 , Apr 11, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Discoidin domain receptor tyrosine kinase 1 (DDR1) Rat and in vitro...
07:00 , Sep 3, 2007 |  BC Week In Review  |  Clinical News

Cellzome preclinical data

Cellzome used its Kinobeads technology to profile the interaction of 3 compounds - Sprycel dasatinib, Gleevec imatinib and SKI-606 bosutinib - with kinases and purine-binding proteins. The data, published in Nature Biotechnology,...